PROGRAM CHAIR

Philippe Moreau, MD
Head of the Hematology Department
Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

PROGRAM OVERVIEW

This educational activity will provide clinicians with the latest evidence on BCMA-targeted therapies for relapsed/refractory multiple myeloma (RRMM), with a focus on the role of bispecific antibodies in the evolving treatment landscape. Faculty will review clinical data supporting current and emerging agents, discuss guideline-based approaches to patient selection and treatment sequencing, and share practical strategies for recognizing, preventing, and managing adverse events associated with bispecific antibody therapy. Through expert insights and evidence-based recommendations, learners will gain the knowledge and confidence to optimize individualized care for patients with RRMM.

TARGET AUDIENCE

This activity is designed to meet the educational needs of European clinicians involved in the evaluation and management of patients with RRMM and NHL, including, but not limited to, hematologists, hematologist/oncologists, oncologists, and advanced practice providers (eg, nurse practitioners, oncology nurses, and physician assistants).

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Utilize clinical data for current and emerging BCMA-targeted agents to identify patients with RRMM who may benefit from bispecific antibodies
• Apply guideline recommendations for personalizing and sequencing treatment for patients with RRMM
• Implement strategies for identifying, mitigating, and treating AEs associated with bispecific antibody therapy in patients with RRMM

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
• Lauren Welch, COO of Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Lauren Scott, PA-C, has nothing to disclose.
• Sarah Milano RN, MSN, has nothing to disclose.
• A medical reviewer from CE Peer Review LLC, has nothing to disclose.
• Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
• Russie Allen, MS, Accreditation and Outcomes Manager, for Med Learning Group, has nothing to disclose.
• Evan Hooper, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, faculty may discuss the use of medications for indications that are approved by the US Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA), as well as indications that have not been approved by one or both regulatory agencies.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASED DATE: August 14, 2026
EXPIRATION DATE: August 14, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.